You are here: Industry Insights > BiondVax

News List

BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment FirstWordPharma
December 30, 2021
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses...
BiondVax signs deals to develop nanosized Covid-19 antibodies Pharmaceutical-Technology
December 24, 2021
BiondVax Pharmaceuticals has entered definitive agreements with the Max Planck Society (MPG) and the University Medical Center Göttingen (UMG) in Germany to develop and market novel Covid-19 nanosized antibodies (NanoAbs).
BiondVax Universal Influenza Vaccine Candidate Trial Does Not Meet Primary, Secondary Endpoints americanpharmaceuticalreview
October 29, 2020
BiondVax Pharmaceuticals announced topline data from the Company's pivotal, phase 3 clinical trial of M-001 as a standalone universal flu vaccine candidate.
BiondVax Moves to New Flu Vaccine Mfg. Facility fiercebiotech
August 22, 2018
BiondVax Pharmaceuticals, developer of the M-001 universal influenza vaccine candidate, has relocated to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel.
BiondVax relocates to new manufacturing facility biospectrumasia
August 21, 2018
BiondVax Pharmaceuticals Ltd. recently reported the company's relocation to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel.
BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States biospace
April 12, 2018
The trial is sponsored by the US National Institute of Allergy and Infectious Disease.
BiondVax receives additional grant funding biospectrumasia
August 18, 2017
Israel innovation authority approves additional budget towards M-001 flu vaccine development
BiondVax Reports Positive Phase 2b Clinical Trial Results for Universal Flu Vaccine americanpharmaceuticalreview
July 21, 2017
BiondVax Pharmaceuticals and the UNISEC consortium reported statistically significant positive results from the Phase 2b clinical trial of M-001, BiondVax's universal flu vaccine candidate.